Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

May 20, 2024

https://www.globenewswire.com/news-release/2024/05/20/2885071/0/en/Korro-Presents-Additional-Preclinical-Data-for-KRRO-110-at-the-American-Thoracic-Society-2024-International-Conference.html

CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) —  Korro Bio, Inc. (Korro) (Nasdaq:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and the completion of a genetic mouse study and sustained editing activity for KRRO-110, its development candidate for the treatment of AATD.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.